XLRN News and Press, Acceleron Pharma Inc. From 11/06/20

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Acceleron Pharma Inc. 2020 Q3 - Results - Earnings Call Presentation

Image source: The Motley Fool. Acceleron Pharma Inc (NASDAQ: XLRN) Q3 2020 Earnings Call Nov 5, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Acceleron Pharma Inc (XLRN) Q3 2020 Earnings Call Transcript

Acceleron Pharma Inc. (XLRN) Q3 2020 Earnings Conference Call October 5, 2020 4:50 PM ET Company Participants Jamie Bernard – Associate Director-Investor Relations Habib Dable – Chief Executive Officer Kevin McLaughlin – Chief Financial Officer Sujay Kango – Chief ...

- Acceleron recognized approximately $19.3 million in royalty revenue for Q3 2020 from approximately $96 million in net sales of REBLOZYL ® (luspatercept-aamt) - - REBLOZYL, the first and only erythroid maturation agent, was approved by Health Canada for the treatment...

- Acceleron expects to report approximately $19.3 million in royalty revenue for Q3 2020 from approximately $96 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb - - Acceleron will report its full third quarter 2020 financial a...

– Data analyses from the Phase 3 MEDALIST and BELIEVE trials find treatment with luspatercept maintains health-related quality of life in patients with lower-risk myelodysplastic syndromes and transfusion-dependent beta-thalassemia, respectively – – Longit...

Acceleron Pharma (NASDAQ:XLRN) is scheduled to announce Q3 earnings results on Thursday, November 5th, after market close.The consensus EPS Estimate is -$0.56 (+34.9% Y/Y) and the consensus Revenue Estimate is $26.52M (+529.9% Y/Y).Over the last 2 years, XLRN has beaten EPS estimates 50% of t...

A Phase 2 clinical trial, ACROBAT Edge, evaluating Crinetics Pharmaceuticals' (CRNX) lead candidate paltusotine (formerly CRN00808) for the treatment of acromegaly met the primary endpoint. Specifically, once-daily oral doses of paltusotine maintained insulin-like growth factor-1 (IGF-1) leve...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quarter 2020 operating and financial results. The webcast will be accessible under "Events & Presentations" in the I...

Acceleron will start a Phase 3 sotatercept for PAH trial by year end. Q3 results should show continuing good Reblozyl revenue ramp. It is possible sotatercept will see commercial sales in 2023 or earlier. For further details see: Acceleron Pharma Plan For Sotatercept Add...